Evolocumab's efficacy was studied in four phase III double-blind, randomized, placebo or active control (ezetimibe) trials spanning 12 weeks. The trials involved more than 3,100 patients, and ...

Results showed mean reduction in LDL-C for the Q2W visits of 63%, 41.3%, and 1.9% for evolocumab 140mg, 70mg, and placebo, respectively (each P <.001 vs 140mg Q2W), while reductions of 62.7%, 55.5 ...

If evolocumab was discounted 29% to $10,311, the ICER is $165,689 per QALY gained, which is still above the threshold considered cost-effective. To achieve an ICER of $150,000, $100,000, and $50,000 ...

Evolocumab reduced by 15 percent the risk of the trial's primary endpoint--a composite of heart attack, stroke, hospitalization for worsening chest pain (angina), revascularization (such as ...

In a second vote, the advisory committee dealt with the use of evolocumab in patients with homozygous FH and unanimously felt the benefits of lowering LDL cholesterol with the PCSK9 inhibitor ...

Patients who were given evolocumab shortly after ACS had rapid and significant LDL reductions in 24 hours, researchers found in the EVACS trial.“The implications for clinical practice are ...

Evolocumab has been on the market since 2015 and was the subject of a very large CV outcome trial in adults (FOURIER; Sabatine MS, et al. N Engl J Med. 2017;doi: 10.1056/NEJMoa1615664.).

(MENAFN- GetNews) "PCSK9 Inhibitors Market"The PCSK9 Inhibitors market size reached ~USD 2 billion in 2023 in 7MM and is ...

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the ...

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or “bad” cholesterol, also significantly lowers the ...

At present, evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi/Regeneron), both of which were approved by the US Food and Drug Administration this summer, cost $14,100 and $14,600 ...

Evolocumab is one of three PCSK9 inhibitors being studied in large clinical trials. One out of three American adults is estimated to have high LDL cholesterol, according to the Centers for Disease ...